544705-16-0Relevant academic research and scientific papers
PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION
-
, (2009/01/23)
The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.
Prodrug substituted benzoxazoles as estrogenic agents
-
Page/Page column 34, (2010/10/20)
This invention provides estrogen receptor modulators of formula I, having the structure wherein Q, Q2, R1, R2, R2a, R3, R3a, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.
Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands
Malamas, Michael S.,Manas, Eric S.,McDevitt, Robert E.,Gunawan, Iwan,Xu, Zhang B.,Collini, Michael D.,Miller, Chris P.,Dinh, Tam,Henderson, Ruth A.,Keith Jr., James C.,Harris, Heather A.
, p. 5021 - 5040 (2007/10/03)
New diphenolic azoles as highly selective estrogen receptor-β agonists are reported. The more potent and selective analogues of these series have comparable binding affinities for ERβ as the natural ligand 17β-estradiol but are > 100-fold selective over ERα. Our design strategy not only followed a traditional SAR approach but also was supported by X-ray structures of ERβ cocrystallized with various ligands as well as molecular modeling studies. These strategies enabled us to take advantage of a single conservative residue substitution in the ligand-binding pocket, ERα Met421 → ERβ Ile373, to optimize ERβ selectivity. The 7-position-substituted benzoxazoles (Table 5) were the most selective ligands of both azole series, with ERB-041 (117) being >200-fold selective for ERβ. The majority of ERβ selective agonists tested that were at least sim;50-fold selective displayed a consistent in vivo profile: they were inactive in several models of classic estrogen action (uterotrophic, osteopenia, and vasomotor instability models) and yet were active in the HLA-B27 transgenic rat model of inflammatory bowel disease. These data suggest that ERβ-selective agonists are devoid of classic estrogenic effects and may offer a novel therapy to treat certain inflammatory conditions.
Substituted benzoxazoles as estrogenic agents
-
, (2008/06/13)
This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.
